AbbVie Secures NMPA Priority Review for Epcoritamab in Relapsed Follicular Lymphoma
American pharmaceutical giant AbbVie (NYSE: ABBV) disclosed that its bispecific T‑cell engager, epcoritamab, has been...
AbbVie
AbbVie Acquires Bretisilocin from Gilgamesh in $1.2B Deal for MDD Treatment
American pharmaceutical giant AbbVie (NYSE: ABBV) has finalized a definitive agreement to acquire bretisilocin, an...
AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth
US-based multinational AbbVie Inc. (NYSE: ABBV) reported strong Q2 2025 results with global revenues increasing...
AbbVie Licenses IGI Therapeutics’ ISB 2001 for Oncology and Autoimmune Diseases
US-based AbbVie (NYSE: ABBV) this week announced a licensing agreement with IGI Therapeutics SA, a...
Guangdong Taienkang Submits Marketing Application for Generic Vuity to China’s NMPA
China-based Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced the submission of a marketing approval...
AbbVie’s Venclexta Approved by China’s NMPA for CLL/SLL Patients with 17p Deletion
US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China’s...
AbbVie to Acquire Capstan Therapeutics for Its First-in-Class CAR-T Candidate
US-based pharmaceutical giant AbbVie (NYSE: ABBV) is poised to acquire fellow American firm Capstan Therapeutics,...
Simcere Zaiming Initiates US Phase I Study of SIM0500 for Relapsed/Refractory Multiple Myeloma
China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary Simcere Zaiming announced the first patient dosing...
AbbVie’s Venclexta Fails to Meet Overall Survival Endpoint in HR-MDS Trial
US-based major AbbVie Inc., (NYSE: ABBV) has revealed disappointing data for its Venclexta (venetoclax) in...
AbbVie’s Mavyret Gains FDA Approval for Acute HCV in Children and Adults
US-based AbbVie (NYSE: ABBV) announced that the US Food and Drug Administration (FDA) has approved...
AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics
US-based pharma giant AbbVie (NYSE: ABBV) has entered into a significant collaboration with ADARx Pharmaceuticals,...
AbbVie’s Rinvoq Gains FDA Approval for Giant Cell Arteritis
US-based pharma giant AbbVie (NYSE: ABBV) announced regulatory approval from the US Food and Drug...
AbbVie Files BLA for TrenibotE in Moderate to Severe Glabellar Lines Treatment
US-based AbbVie (NYSE: ABBV) announced that it has filed a Biologics License Application (BLA) with...
Zhaoke Ophthalmology Enrolls First Patient for Cyclosporine A Eye Gel Phase III Study
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the first patient enrollment in a Phase...
AbbVie’s Rinvoq Approved in EU for Giant Cell Arteritis
US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval in the...
AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development
US pharmaceutical giant AbbVie (NYSE: ABBV) has filed a lawsuit in the U.S. District Court...
Huadong Medicine Seeks Regular Approval for Elahere in Ovarian Cancer Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its application for converting conditional to...
AbbVie’s Skyrizi Approved by China’s NMPA for Moderate to Severe Crohn’s Disease
US giant AbbVie (NYSE: ABBV) announced receiving marketing approval from China’s National Medical Products Administration...
AbbVie Enters Obesity Field with Gubra’s GUB014295 Licensing Deal
US pharmaceutical giant AbbVie (NYSE: ABBV) announced that it is making significant progress in the...
AbbVie Collaborates with Xilio Therapeutics on Tumor-Activated Immunotherapies
US pharmaceutical giant AbbVie (NYSE: ABBV) has announced a collaboration and option-to-license agreement with fellow...